How to Get Jatenzo in Arizona

What Jatenzo Is and Why Prescribers in Arizona Choose It

Jatenzo is the only FDA-approved oral testosterone undecanoate capsule in the United States, approved in March 2019 for adult males with hypogonadism caused by specific medical conditions. Unlike intramuscular testosterone cypionate or enanthate, it is absorbed through intestinal lymphatics, which bypasses first-pass hepatic metabolism. Prescribers in Arizona often recommend it for patients who refuse injections, have needle phobias, or need a discreet, portable dosing option that fits an active outdoor lifestyle common to the state.

The key Phase III study by Swerdloff et al. (J Clin Endocrinol Metab, 2020, N=166) demonstrated that 87% of men achieved average serum testosterone concentrations within the normal eugonadal range (300 to 1 to 050 ng/dL) during the 12-week maintenance phase [1]. The FDA label requires titration: the starting dose is 237 mg twice daily with food, adjustable to 158 mg or 396 mg twice daily based on a testosterone level drawn 4 to 5 hours after the morning dose at week 3 or 5 [2].

Because each capsule must be taken with a meal containing at least 10 to 15 grams of fat, patient counseling on timing is a standard part of every Arizona telehealth visit. Swerdloff et al. noted that "the lymphatic absorption pathway of [oral testosterone undecanoate] bypasses hepatic first pass, resulting in no clinically meaningful changes in liver enzymes at therapeutic doses" [1]. That hepatic safety profile separates Jatenzo from older 17-alpha-alkylated oral androgens that carried significant liver toxicity.

Arizona Telehealth Laws and Jatenzo Prescribing

Arizona is one of the more permissive states for telehealth prescribing of controlled substances. Jatenzo is a Schedule III controlled substance under the DEA. Under Arizona Revised Statutes §32-1401 and the state's telehealth framework adopted after federal COVID-era waivers, a prescriber may initiate a Schedule III prescription via synchronous audio-video telehealth without a prior in-person visit, provided that a valid prescriber-patient relationship is established during the visit [3].

That is a meaningful distinction. Arizona does not require a prior in-person physical exam before a telehealth provider can prescribe Jatenzo, as long as the clinician reviews the patient's lab results, medical history, and conducts a real-time video assessment. Several national telehealth platforms, including HealthRX, maintain Arizona-licensed prescribers specifically for this reason.

The DEA's 2023 proposed rules on telemedicine prescribing of controlled substances created concern for many patients, but Schedule III non-narcotic substances like testosterone products have remained accessible via telehealth under the ongoing telemedicine exemptions, which were extended through the end of 2025 [4]. Patients should confirm their telehealth provider holds an active Arizona medical license and a DEA registration that lists Arizona as a state of practice before booking.

Who Can Prescribe Jatenzo in Arizona

Arizona has broad scope-of-practice laws. Three categories of clinicians hold independent authority to prescribe Schedule III controlled substances in this state.

Medical doctors (MD) and doctors of osteopathic medicine (DO) have unrestricted prescribing authority and can manage complex cases involving cardiovascular comorbidities or secondary hypogonadism.

Nurse practitioners (NP) in Arizona practice under full independent authority per ARS §32-1606, with no physician collaboration agreement required. An NP with a DEA registration may write a Jatenzo prescription without physician co-signature [5].

Physician assistants (PA) in Arizona require a supervising physician agreement under ARS §32-2536 but may prescribe Schedule III substances within that agreement's scope. In practice, most PA-run telehealth clinics have a supervising physician on record, so the patient experience is identical.

Endocrinologists, urologists, and men's health primary care physicians are the most common face-to-face prescribers. For telehealth, internal medicine-trained clinicians who specialize in hormone optimization now represent a growing share of new Jatenzo prescriptions in the Southwest.

Required Labs Before Getting a Jatenzo Prescription in Arizona

No responsible clinician will prescribe testosterone without a baseline laboratory panel. Arizona law does not prescribe a specific panel by statute, but the Endocrine Society's 2018 clinical practice guideline on male hypogonadism specifies a minimum workup [6]. The standard pre-Jatenzo panel used by Arizona telehealth providers includes the following tests.

Morning serum total testosterone: Drawn between 7 a.m. and 10 a.m. on two separate occasions. The Endocrine Society defines hypogonadism as a consistently low serum testosterone concentration combined with signs and symptoms; a single low reading is insufficient for diagnosis [6]. The diagnostic threshold used in most Arizona practices is below 300 ng/dL on two morning draws.

LH and FSH: Differentiates primary from secondary hypogonadism. Secondary hypogonadism (low testosterone with low or inappropriately normal LH) may point to a pituitary lesion requiring MRI before testosterone therapy begins.

Hematocrit (or complete blood count): Baseline hematocrit above 50% is a contraindication to starting Jatenzo per the FDA label [2]. Testosterone stimulates erythropoiesis, and uncontrolled polycythemia raises thrombotic risk.

PSA: Required in men 40 and older. A PSA above 4.0 ng/mL or a rapid rise from baseline warrants urology referral before testosterone initiation per AUA guidelines.

Comprehensive metabolic panel (CMP): Assesses hepatic and renal function, relevant given Jatenzo's gastrointestinal absorption and the metabolic comorbidities common in hypogonadal men.

Blood pressure measurement: Jatenzo carries an FDA black-box warning for increases in blood pressure and a warning against use in patients with current or high-risk cardiovascular disease. Arizona telehealth providers routinely require a recent blood pressure reading, either self-reported from a home cuff or from a recent clinic visit [2].

Most Arizona LabCorp and Quest Diagnostics locations can complete this panel in a single morning draw. Results are typically available within 24 to 48 hours and can be uploaded directly to a telehealth portal. HealthRX can provide a lab order for Arizona patients who do not yet have a primary care provider.

Step-by-Step: How to Get a Jatenzo Prescription in Arizona

The process from first inquiry to first dose follows five distinct steps, and the total elapsed time varies from 7 days (expedited telehealth with rapid labs) to 21 days (in-person referral with insurance prior authorization).

Step 1. Complete an intake form and symptom questionnaire. Arizona telehealth platforms collect medical history, current medications, and symptom burden using validated instruments such as the Androgen Deficiency in Aging Males (ADAM) questionnaire or the International Index of Erectile Function (IIEF-5). A positive ADAM screen alone does not qualify a patient; it initiates the lab workup.

Step 2. Get lab work drawn. Patients use a telehealth-provided lab requisition at any Arizona LabCorp or Quest site. The two-draw protocol for testosterone (on separate mornings) adds 24 to 48 hours to the timeline. HealthRX coordinates same-week appointments at over 40 draw sites across the Phoenix metro, Tucson, Flagstaff, and Scottsdale.

Step 3. Synchronous telehealth consultation. Once lab results are received, a licensed Arizona prescriber reviews them during a 20 to 30-minute video visit. The prescriber confirms clinical hypogonadism, rules out contraindications (hematocrit above 50%, untreated severe sleep apnea, prostate or breast cancer, BP above 165/100 mmHg), and counsels the patient on the fat-with-food dosing requirement.

Step 4. Prescription transmission and pharmacy routing. The prescriber sends a DEA-compliant e-prescription to the patient's preferred Arizona pharmacy or a mail-order pharmacy licensed in Arizona. Jatenzo is stocked at larger retail chains including CVS, Walgreens, and Costco pharmacy in the Phoenix and Tucson markets, though availability varies by location. Specialty mail-order pharmacies that ship to Arizona addresses (where Arizona state law permits) can deliver within 2 to 5 business days.

Step 5. Titration follow-up at week 3 to 5. The FDA label requires a follow-up testosterone draw 4 to 5 hours after the morning dose at week 3 or 5 to guide dose adjustment. Arizona telehealth providers schedule this as a brief asynchronous lab review or a short follow-up video call. Missing this step is the single most common clinical error in oral testosterone management.

Insurance, Prior Authorization, and Cash-Pay Options in Arizona

Jatenzo's list price is approximately $550 to $650 per month for 60 capsules (237 mg twice daily). Most commercial insurers in Arizona, including BCBS of Arizona, UnitedHealthcare, and Cigna, cover Jatenzo under their pharmacy benefit for male hypogonadism but require prior authorization (PA).

A standard Jatenzo prior authorization in Arizona requires three categories of documentation.

First, clinical documentation: two morning serum testosterone results below 300 ng/dL, a confirmed diagnosis of primary or secondary hypogonadism with an ICD-10 code (E29.1 or E23.0), and a note documenting signs or symptoms consistent with hypogonadism.

Second, step therapy evidence: many Arizona commercial plans require documented failure or intolerance of at least one injectable testosterone formulation (testosterone cypionate or enanthate) or a documented clinical reason why injections are contraindicated, such as a coagulopathy or patient refusal.

Third, prescriber attestation: the prescriber completes a PA form confirming the patient's cardiovascular risk status, baseline blood pressure, and absence of active or high-risk prostate disease.

PA approvals in Arizona typically return within 3 to 7 business days when submitted electronically through CoverMyMeds or the insurer's provider portal. Denials are most often overturned on first-level appeal when the prescriber provides the second testosterone level and clinical notes.

Arizona Medicaid (AHCCCS) does not cover Jatenzo for male hypogonadism, as confirmed by the state's preferred drug list [7]. Patients on AHCCCS are typically managed with injectable testosterone cypionate, which AHCCCS does cover.

For cash-pay patients, Tolmar's Jatenzo savings program (available at Jatenzo.com and printable at the pharmacy) can reduce out-of-pocket cost to approximately $99 per month for eligible commercially insured patients. Uninsured patients may qualify for manufacturer patient assistance programs reviewed annually by Tolmar's medical affairs team.

Arizona 503A Pharmacies and Oral Testosterone Compounding

A 503A compounding pharmacy in Arizona may prepare oral testosterone undecanoate capsules for a specific patient with a valid prescription, as long as the preparation meets USP <795> standards and the pharmacist does not essentially copy the FDA-approved Jatenzo product. However, a critical regulatory point separates compounded oral testosterone from Jatenzo.

The FDA's 2020 guidance on compounding and the DSCSA (Drug Supply Chain Security Act) makes clear that a 503A pharmacy cannot compound a drug that is "essentially a copy" of an approved finished drug product without a specific clinical difference documented by the prescriber [8]. Because Jatenzo is approved at a fixed strength (237 mg), a prescriber seeking a different strength (such as 100 mg or 200 mg) can document a patient-specific clinical rationale, and a licensed Arizona 503A pharmacy may then prepare that formulation.

In practice, most Arizona telehealth providers prescribe brand Jatenzo when the patient has insurance, and route cash-pay patients either to the manufacturer savings program or to 503A-compounded oral testosterone undecanoate at a different dose if a clinical distinction is documented. Oral testosterone compounding carries no FDA bioavailability or safety data equivalent to the Swerdloff key trial, so providers who default to compounded oral testosterone without clinical justification take on elevated medicolegal exposure.

Managing Blood Pressure: Jatenzo's Black Box Warning

Jatenzo's FDA label carries a black box warning that it "can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE)" [2]. This is not a minor footnote. It is the central safety monitoring requirement for every Jatenzo patient.

The Swerdloff Phase III trial reported a mean systolic blood pressure increase of 3.5 mmHg and a mean diastolic increase of 1.5 mmHg from baseline over 12 weeks in the active treatment arm [1]. At a population level, a 3 to 4 mmHg systolic rise is associated with a measurable increase in cardiovascular event rates, as modeled in Framingham risk data.

Arizona telehealth providers following HealthRX's clinical protocols check blood pressure at baseline, at the week 3 to 5 titration visit, and at each subsequent quarterly follow-up. Patients with pre-existing stage 2 hypertension (BP above 140/90 mmHg at baseline) receive antihypertensive optimization before Jatenzo is started, not after. Patients with a recent myocardial infarction or stroke in the prior 6 months are not started on Jatenzo per the label contraindications [2].

Monitoring Schedule for Arizona Jatenzo Patients

After the initial titration visit, the standard monitoring schedule for Jatenzo in Arizona follows the Endocrine Society and AUA joint recommendations [6]:

At 3 months: testosterone level (4 to 5 hours post-morning dose), hematocrit, blood pressure, symptom reassessment.

At 6 months: repeat hematocrit, PSA (men over 40), blood pressure, testosterone if dose was adjusted.

Annually: full panel including testosterone, CMP, lipids, hematocrit, PSA, and blood pressure. Bone density (DXA) is recommended at baseline and every 1 to 2 years in men with osteoporosis risk.

Hematocrit above 54% at any point requires dose reduction or temporary discontinuation per the FDA label. Persistent hematocrit above 54% despite dose reduction warrants phlebotomy evaluation and hematology referral.

Transferring an Existing Jatenzo Prescription to Arizona

Patients relocating to Arizona from another state can transfer a Jatenzo prescription under specific conditions. Jatenzo is a Schedule III controlled substance. Under DEA regulations, Schedule III prescriptions may be transferred between pharmacies only once (for non-refillable prescriptions) or multiple times if the original was issued with refills authorized, but electronic prescribing systems in most states allow transfers through shared real-time databases [9].

The simpler route for most patients is to establish care with an Arizona-licensed prescriber, bring records and recent lab work from their prior provider, and receive a new Arizona Rx rather than attempting an interstate pharmacy transfer. Arizona telehealth platforms can schedule a new-patient visit within 24 to 48 hours for returning testosterone therapy patients with existing labs less than 6 months old, allowing same-week prescription issuance without repeating the full baseline panel.

How Long Until You Receive Jatenzo in Arizona

Timeline varies by route to prescription. The fastest path is an Arizona telehealth platform that provides a lab requisition, has relationships with same-week draw sites, and can complete the prescriber visit within 24 hours of lab results returning. In that scenario, patients in Phoenix, Tucson, Tempe, Mesa, Chandler, or Scottsdale can receive a Jatenzo prescription within 5 to 7 days of first contact and pick it up at a local pharmacy the same day it is transmitted.

Patients going through a primary care referral to endocrinology should expect 4 to 8 weeks for an appointment, plus the lab timeline, plus insurance PA processing. The in-person route is slower but may be appropriate for men with complex comorbidities, secondary hypogonadism requiring pituitary imaging, or fertility concerns requiring specialist input.